Farnesoid X receptor: A “homeostat” for hepatic nutrient metabolism

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1864, Issue 1, 2018, Pages 45-59

  Massafra, Vittoria ^a   van Mil, Saskia W C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Autophagy; Bile acids; FXR; Inflammation; Nutrient metabolism; Proliferation

Indexed keywords

AMINO ACID; BILE ACID; FARNESOID X RECEPTOR; GLUCOSE; LIPID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR;

ABSORPTION; AMINO ACID METABOLISM; AUTOPHAGY; CELL FATE; CELL PROLIFERATION; ENERGY METABOLISM; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; LIPID METABOLISM; LIVER; LIVER DISEASE; METABOLISM; NONHUMAN; NUTRIENT; NUTRIENT AVAILABILITY; NUTRITION; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; STARVATION; ANIMAL; FOOD; GENETICS; HOMEOSTASIS; INTESTINE; LIVER CELL; PHYSIOLOGY;

ANIMALS; BILE ACIDS AND SALTS; ENERGY METABOLISM; FOOD; GLUCOSE; HEPATOCYTES; HOMEOSTASIS; HUMANS; INTESTINES; LIVER; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 85031729904     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2017.10.003     Document Type: Review

References (215)

1. Mangelsdorf, D.J., Evans, R.M., The RXR heterodimers and orphan receptors. Cell 83:6 (1995), 841–850.
2. Aranda, A., Pascual, A., Nuclear hormone receptors and gene expression. Physiol. Rev. 81:3 (2001), 1269–1304.
3. Sundahl, N., Bridelance, J., Libert, C., De Bosscher, K., Beck, I.M., Selective glucocorticoid receptor modulation: new directions with non-steroidal scaffolds. Pharmacol. Ther. 152 (2015), 28–41.
4. Bijsmans, I.T., Guercini, C., Ramos Pittol, J.M. et al., The glucocorticoid mometasone furoate is a novel FXR ligand that decreases inflammatory but not metabolic gene expression. Sci Rep, 5, 2015, 14086.
5. Vacca, M., Degirolamo, C., Mariani-Costantini, R., Palasciano, G., Moschetta, A., Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome. Wiley Interdiscip. Rev. Syst. Biol. Med. 3:5 (2011), 562–587.
6. Francis, G.A., Fayard, E., Picard, F., Auwerx, J., Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. 65 (2003), 261–311.
7. Otte, K., Kranz, H., Kober, I. et al., Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol. Cell. Biol. 23:3 (2003), 864–872.
8. Huber, R.M., Murphy, K., Miao, B. et al., Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 290:1–2 (2002), 35–43.
9. Zhang, Y., Kast-Woelbern, H.R., Edwards, P.A., Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J. Biol. Chem. 278:1 (2003), 104–110.
10. Correia, J.C., Massart, J., de Boer, J.F. et al., Bioenergetic cues shift FXR splicing towards FXRalpha2 to modulate hepatic lipolysis and fatty acid metabolism. Mol. Metab. 4:12 (2015), 891–902.
11. Chen, Y., Song, X., Valanejad, L. et al., Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma. Hepatology 57:4 (2013), 1530–1541.
12. Gineste, R., Sirvent, A., Paumelle, R. et al., Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. Mol. Endocrinol. 22:11 (2008), 2433–2447.
13. Kemper, J.K., Xiao, Z., Ponugoti, B. et al., FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab. 10:5 (2009), 392–404.
14. Balasubramaniyan, N., Luo, Y., Sun, A.Q., Suchy, F.J., SUMOylation of the farnesoid X receptor (FXR) regulates the expression of FXR target genes. J. Biol. Chem. 288:19 (2013), 13850–13862.
15. Kim, D.H., Xiao, Z., Kwon, S. et al., A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity. EMBO J. 34:2 (2015), 184–199.
16. Berrabah, W., Aumercier, P., Gheeraert, C. et al., Glucose sensing O-GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR). Hepatology 59:5 (2014), 2022–2033.
17. Viscarra, J.A., Ortiz, R.M., Cellular mechanisms regulating fuel metabolism in mammals: role of adipose tissue and lipids during prolonged food deprivation. Metabolism 62:7 (2013), 889–897.
18. Forman, B.M., Goode, E., Chen, J. et al., Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81:5 (1995), 687–693.
19. Makishima, M., Okamoto, A.Y., Repa, J.J. et al., Identification of a nuclear receptor for bile acids. Science 284:5418 (1999), 1362–1365.
20. Parks, D.J., Blanchard, S.G., Bledsoe, R.K. et al., Bile acids: natural ligands for an orphan nuclear receptor. Science 284:5418 (1999), 1365–1368.
21. Wang, H., Chen, J., Hollister, K., Sowers, L.C., Forman, B.M., Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 3:5 (1999), 543–553.
22. Dawson, P.A., Haywood, J., Craddock, A.L. et al., Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J. Biol. Chem. 278:36 (2003), 33920–33927.
23. Grober, J., Zaghini, I., Fujii, H. et al., Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer. J. Biol. Chem. 274:42 (1999), 29749–29754.
24. Dawson, P.A., Hubbert, M., Haywood, J. et al., The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter. J. Biol. Chem. 280:8 (2005), 6960–6968.
25. Rao, A., Haywood, J., Craddock, A.L., Belinsky, M.G., Kruh, G.D., Dawson, P.A., The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis. Proc. Natl. Acad. Sci. U. S. A. 105:10 (2008), 3891–3896.
26. Ridlon, J.M., Kang, D.J., Hylemon, P.B., Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47:2 (2006), 241–259.
27. Slijepcevic, D., Kaufman, C., Wichers, C.G. et al., Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na(+) -taurocholate cotransporting polypeptide knockout mice. Hepatology 62:1 (2015), 207–219.
28. Hagenbuch, B., Meier, P.J., Molecular cloning, chromosomal localization, and functional characterization of a human liver Na +/bile acid cotransporter. J. Clin. Invest. 93:3 (1994), 1326–1331.
29. Hagenbuch, B., Meier, P.J., The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta 1609:1 (2003), 1–18.
30. Csanaky, I.L., Lu, H., Zhang, Y., Ogura, K., Choudhuri, S., Klaassen, C.D., Organic anion-transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: studies in Oatp1b2-null mice. Hepatology 53:1 (2011), 272–281.
31. Falany, C.N., Johnson, M.R., Barnes, S., Diasio, R.B., Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA:amino acid N-acyltransferase. J. Biol. Chem. 269:30 (1994), 19375–19379.
32. Lin, B.C., Wang, M., Blackmore, C., Desnoyers, L.R., Liver-specific activities of FGF19 require Klotho beta. J. Biol. Chem. 282:37 (2007), 27277–27284.
33. de Aguiar Vallim, T.Q., Tarling, E.J., Ahn, H. et al., MAFG is a transcriptional repressor of bile acid synthesis and metabolism. Cell Metab. 21:2 (2015), 298–310.
34. Kong, B., Wang, L., Chiang, J.Y., Zhang, Y., Klaassen, C.D., Guo, G.L., Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 56:3 (2012), 1034–1043.
35. Sinal, C.J., Tohkin, M., Miyata, M., Ward, J.M., Lambert, G., Gonzalez, F.J., Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102:6 (2000), 731–744.
36. Ananthanarayanan, M., Balasubramanian, N., Makishima, M., Mangelsdorf, D.J., Suchy, F.J., Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 276:31 (2001), 28857–28865.
37. Liu, Y., Binz, J., Numerick, M.J. et al., Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J. Clin. Invest. 112:11 (2003), 1678–1687.
38. Dawson, P.A., Hubbert, M.L., Rao, A., Getting the mOST from OST: role of organic solute transporter, OSTalpha-OSTbeta, in bile acid and steroid metabolism. Biochim. Biophys. Acta 1801:9 (2010), 994–1004.
39. Landrier, J.F., Eloranta, J.J., Vavricka, S.R., Kullak-Ublick, G.A., The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes. Am. J. Physiol. Gastrointest. Liver Physiol. 290:3 (2006), G476–485.
40. Lee, H., Zhang, Y., Lee, F.Y., Nelson, S.F., Gonzalez, F.J., Edwards, P.A.F.X.R., regulates organic solute transporters alpha and beta in the adrenal gland, kidney, and intestine. J. Lipid Res. 47:1 (2006), 201–214.
41. Fu, T., Kim, Y.C., Byun, S. et al., FXR primes the liver for intestinal FGF15 signaling by transient induction of beta-Klotho. Mol. Endocrinol. 30:1 (2016), 92–103.
42. Zhou, H., Hylemon, P.B., Bile acids are nutrient signaling hormones. Steroids 86 (2014), 62–68.
43. Makishima, M., TT, Lu, Xie, W. et al., Vitamin D receptor as an intestinal bile acid sensor. Science 296:5571 (2002), 1313–1316.
44. Staudinger, J.L., Goodwin, B., Jones, S.A. et al., The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. U. S. A. 98:6 (2001), 3369–3374.
45. Huang, W., Zhang, J., Chua, S.S. et al., Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc. Natl. Acad. Sci. U. S. A. 100:7 (2003), 4156–4161.
46. Zelko, I., Sueyoshi, T., Kawamoto, T., Moore, R., Negishi, M., The peptide near the C terminus regulates receptor CAR nuclear translocation induced by xenochemicals in mouse liver. Mol. Cell. Biol. 21:8 (2001), 2838–2846.
47. Kawamata, Y., Fujii, R., Hosoya, M. et al., A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278:11 (2003), 9435–9440.
48. Watanabe, M., Houten, S.M., Mataki, C. et al., Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439:7075 (2006), 484–489.
49. Lowe, M.E., Structure and function of pancreatic lipase and colipase. Annu. Rev. Nutr. 17 (1997), 141–158.
50. Mu, H., Hoy, C.E., The digestion of dietary triacylglycerols. Prog. Lipid Res. 43:2 (2004), 105–133.
51. Goldberg, I.J., Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J. Lipid Res. 37:4 (1996), 693–707.
52. Havel, R.J., Receptor and non-receptor mediated uptake of chylomicron remnants by the liver. Atherosclerosis 141:Suppl. 1 (1998), S1–7.
53. Czech, M.P., Tencerova, M., Pedersen, D.J., Aouadi, M., Insulin signalling mechanisms for triacylglycerol storage. Diabetologia 56:5 (2013), 949–964.
54. Rui, L., Energy metabolism in the liver. Compr. Physiol. 4:1 (2014), 177–197.
55. Wang, Y., Viscarra, J., Kim, S.J., Sul, H.S., Transcriptional regulation of hepatic lipogenesis. Nat. Rev. Mol. Cell Biol. 16:11 (2015), 678–689.
56. Yecies, J.L., Zhang, H.H., Menon, S. et al., Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab. 14:1 (2011), 21–32.
57. Shimano, H., Shimomura, I., Hammer, R.E. et al., Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. J. Clin. Invest. 100:8 (1997), 2115–2124.
58. Jeon, T.I., Osborne, T.F. SREBPs, metabolic integrators in physiology and metabolism. Trends Endocrinol. Metab. 23:2 (2012), 65–72.
59. Iizuka, K., Bruick, R.K., Liang, G., Horton, J.D., Uyeda, K., Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc. Natl. Acad. Sci. U. S. A. 101:19 (2004), 7281–7286.
60. Denechaud, P.D., Bossard, P., Lobaccaro, J.M. et al., ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver. J. Clin. Invest. 118:3 (2008), 956–964.
61. Filhoulaud, G., Guilmeau, S., Dentin, R., Girard, J., Postic, C., Novel insights into ChREBP regulation and function. Trends Endocrinol. Metab. 24:5 (2013), 257–268.
62. Chen, W., Chen, G., Head, D.L., Mangelsdorf, D.J., Russell, D.W., Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. Cell Metab. 5:1 (2007), 73–79.
63. Janowski, B.A., Willy, P.J., Devi, T.R., Falck, J.R., Mangelsdorf, D.J., An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383:6602 (1996), 728–731.
64. Joseph, S.B., Laffitte, B.A., Patel, P.H. et al., Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J. Biol. Chem. 277:13 (2002), 11019–11025.
65. Jamil, H., Chu, C.H., Dickson, J.K. Jr. et al., Evidence that microsomal triglyceride transfer protein is limiting in the production of apolipoprotein B-containing lipoproteins in hepatic cells. J. Lipid Res. 39:7 (1998), 1448–1454.
66. Tietge, U.J., Bakillah, A., Maugeais, C., Tsukamoto, K., Hussain, M., Rader, D.J., Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased in vivo secretion of VLDL triglycerides and apolipoprotein B. J. Lipid Res. 40:11 (1999), 2134–2139.
67. Sundaram, M., Zhong, S., Bou Khalil, M. et al., Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia. J. Lipid Res. 51:6 (2010), 1524–1534.
68. Kamagate, A., Dong, H.H., FoxO1 integrates insulin signaling to VLDL production. Cell Cycle 7:20 (2008), 3162–3170.
69. Kamagate, A., Qu, S., Perdomo, G. et al., FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J. Clin. Invest. 118:6 (2008), 2347–2364.
70. Haas, M.E., Attie, A.D., Biddinger, S.B., The regulation of ApoB metabolism by insulin. Trends Endocrinol. Metab. 24:8 (2013), 391–397.
71. Wade, D.P., Knight, B.L., Soutar, A.K., Regulation of low-density-lipoprotein-receptor mRNA by insulin in human hepatoma Hep G2 cells. Eur. J. Biochem. 181:3 (1989), 727–731.
72. Ameen, C., Edvardsson, U., Ljungberg, A. et al., Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver. J. Biol. Chem. 280:2 (2005), 1224–1229.
73. Sheena, V., Hertz, R., Nousbeck, J., Berman, I., Magenheim, J., Bar-Tana, J., Transcriptional regulation of human microsomal triglyceride transfer protein by hepatocyte nuclear factor-4alpha. J. Lipid Res. 46:2 (2005), 328–341.
74. Wolfrum, C., Stoffel, M., Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion. Cell Metab. 3:2 (2006), 99–110.
75. Bruinstroop, E., la Fleur, S.E., Ackermans, M.T. et al., The autonomic nervous system regulates postprandial hepatic lipid metabolism. Am. J. Physiol. Endocrinol. Metab. 304:10 (2013), E1089–1096.
76. Bateson, M.C., Maclean, D., Evans, J.R., Bouchier, I.A., Chenodeoxycholic acid therapy for hypertriglyceridaemia in men. Br. J. Clin. Pharmacol. 5:3 (1978), 249–254.
77. Leiss, O., von Bergmann, K., Different effects of chenodeoxycholic acid and ursodeoxycholic acid on serum lipoprotein concentrations in patients with radiolucent gallstones. Scand. J. Gastroenterol. 17:5 (1982), 587–592.
78. Crouse, J.R. 3rd, Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am. J. Med. 83:2 (1987), 243–248.
79. Zhang, Y., Lee, F.Y., Barrera, G. et al., Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 103:4 (2006), 1006–1011.
80. Kunne, C., Acco, A., Duijst, S. et al., FXR-dependent reduction of hepatic steatosis in a bile salt deficient mouse model. Biochim. Biophys. Acta 1842:5 (2014), 739–746.
81. Kast, H.R., Nguyen, C.M., Sinal, C.J. et al., Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol. Endocrinol. 15:10 (2001), 1720–1728.
82. Claudel, T., Inoue, Y., Barbier, O. et al., Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 125:2 (2003), 544–555.
83. Watanabe, M., Houten, S.M., Wang, L. et al., Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 113:10 (2004), 1408–1418.
84. Ma, K., Saha, P.K., Chan, L., Moore, D.D., Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest. 116:4 (2006), 1102–1109.
85. Pineda Torra, I., Claudel, T., Duval, C., Kosykh, V., Fruchart, J.C., Staels, B., Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol. Endocrinol. 17:2 (2003), 259–272.
86. Xu, J., Li, Y., Chen, W.D. et al., Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis. Hepatology 59:5 (2014), 1761–1771.
87. Savkur, R.S., Bramlett, K.S., Michael, L.F., Burris, T.P., Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor. Biochem. Biophys. Res. Commun. 329:1 (2005), 391–396.
88. Bilz, S., Samuel, V., Morino, K., Savage, D., Choi, C.S., Shulman, G.I., Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters. Am. J. Physiol. Endocrinol. Metab. 290:4 (2006), E716–722.
89. Miller, N.E., Nestel, P.J., Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia. Lancet 2:7886 (1974), 929–931.
90. Hirokane, H., Nakahara, M., Tachibana, S., Shimizu, M., Sato, R., Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J. Biol. Chem. 279:44 (2004), 45685–45692.
91. Liu, Q., Yang, M., Fu, X. et al., Activation of farnesoid X receptor promotes triglycerides lowering by suppressing phospholipase A2 G12B expression. Mol. Cell. Endocrinol. 436 (2016), 93–101.
92. Mak, P.A., Kast-Woelbern, H.R., Anisfeld, A.M., Edwards, P.A., Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. J. Lipid Res. 43:12 (2002), 2037–2041.
93. Urizar, N.L., Dowhan, D.H., Moore, D.D., The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. J. Biol. Chem. 275:50 (2000), 39313–39317.
94. Lambert, G., Amar, M.J., Guo, G., Brewer, H.B. Jr., Gonzalez, F.J., Sinal, C.J., The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J. Biol. Chem. 278:4 (2003), 2563–2570.
95. Li, L., Liu, H., Peng, J. et al., Farnesoid X receptor up-regulates expression of lipid transfer inhibitor protein in liver cells and mice. Biochem. Biophys. Res. Commun. 441:4 (2013), 880–885.
96. Barter, P.J., Brewer, H.B. Jr., Chapman, M.J., Hennekens, C.H., Rader, D.J., Tall, A.R., Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23:2 (2003), 160–167.
97. Holt, J.A., Luo, G., Billin, A.N. et al., Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17:13 (2003), 1581–1591.
98. Inagaki, T., Choi, M., Moschetta, A. et al., Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2:4 (2005), 217–225.
99. Tomlinson, E., Fu, L., John, L. et al., Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143:5 (2002), 1741–1747.
100. Fu, L., John, L.M., Adams, S.H. et al., Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145:6 (2004), 2594–2603.
101. Bhatnagar, S., Damron, H.A., Hillgartner, F.B., Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J. Biol. Chem. 284:15 (2009), 10023–10033.
102. Miyata, M., Sakaida, Y., Matsuzawa, H., Yoshinari, K., Yamazoe, Y., Fibroblast growth factor 19 treatment ameliorates disruption of hepatic lipid metabolism in farnesoid X receptor (Fxr)-null mice. Biol. Pharm. Bull. 34:12 (2011), 1885–1889.
103. Schmitt, J., Kong, B., Stieger, B. et al., Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal. Liver Int. 35:4 (2015), 1133–1144.
104. Duran-Sandoval, D., Cariou, B., Percevault, F. et al., The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J. Biol. Chem. 280:33 (2005), 29971–29979.
105. Zhang, Y., Castellani, L.W., Sinal, C.J., Gonzalez, F.J., Edwards, P.A., Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev. 18:2 (2004), 157–169.
106. Shi, L., Tu, B.P., Acetyl-CoA and the regulation of metabolism: mechanisms and consequences. Curr. Opin. Cell Biol. 33 (2015), 125–131.
107. Park, J.M., Jo, S.H., Kim, M.Y., Kim, T.H., Ahn, Y.H., Role of transcription factor acetylation in the regulation of metabolic homeostasis. Protein Cell. 6:11 (2015), 804–813.
108. Fang, S., Tsang, S., Jones, R. et al., The p300 acetylase is critical for ligand-activated farnesoid X receptor (FXR) induction of SHP. J. Biol. Chem. 283:50 (2008), 35086–35095.
109. Kay, H.Y., Kim, W.D., Hwang, S.J. et al., Nrf2 inhibits LXRalpha-dependent hepatic lipogenesis by competing with FXR for acetylase binding. Antioxid. Redox Signal. 15:8 (2011), 2135–2146.
110. Hardie, D.G., Alessi, D.R., LKB1 and AMPK and the cancer-metabolism link — ten years after. BMC Biol., 11, 2013, 36.
111. Lien, F., Berthier, A., Bouchaert, E. et al., Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. J. Clin. Invest. 124:3 (2014), 1037–1051.
112. Levin, R.J., Digestion and absorption of carbohydrates—from molecules and membranes to humans. Am. J. Clin. Nutr. 59:3 Suppl (1994), 690S–698S.
113. Wright, E.M., Martin, M.G., Turk, E., Intestinal absorption in health and disease—sugars. Best Pract. Res. Clin. Gastroenterol. 17:6 (2003), 943–956.
114. Chandel, N.S., Navigating metabolism. Cold Spring Harbor, 2015, Cold Spring Harbor Laboratory Press, New York, 128.
115. Moore, M.C., Cherrington, A.D., Wasserman, D.H., Regulation of hepatic and peripheral glucose disposal. Best Pract. Res. Clin. Endocrinol. Metab. 17:3 (2003), 343–364.
116. Agius, L., Glucokinase and molecular aspects of liver glycogen metabolism. Biochem. J. 414:1 (2008), 1–18.
117. Roth, U., Curth, K., Unterman, T.G., Kietzmann, T., The transcription factors HIF-1 and HNF-4 and the coactivator p300 are involved in insulin-regulated glucokinase gene expression via the phosphatidylinositol 3-kinase/protein kinase B pathway. J. Biol. Chem. 279:4 (2004), 2623–2631.
118. Roth, U., Jungermann, K., Kietzmann, T., Activation of glucokinase gene expression by hepatic nuclear factor 4alpha in primary hepatocytes. Biochem. J. 365:Pt 1 (2002), 223–228.
119. Kim, T.H., Kim, H., Park, J.M. et al., Interrelationship between liver X receptor alpha, sterol regulatory element-binding protein-1c, peroxisome proliferator-activated receptor gamma, and small heterodimer partner in the transcriptional regulation of glucokinase gene expression in liver. J. Biol. Chem. 284:22 (2009), 15071–15083.
120. Puigserver, P., Rhee, J., Donovan, J. et al., Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 423:6939 (2003), 550–555.
121. Bricambert, J., Miranda, J., Benhamed, F., Girard, J., Postic, C., Dentin, R., Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice. J. Clin. Invest. 120:12 (2010), 4316–4331.
122. Guinez, C., Filhoulaud, G., Rayah-Benhamed, F. et al., O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver. Diabetes 60:5 (2011), 1399–1413.
123. Yamashita, H., Takenoshita, M., Sakurai, M. et al., A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc. Natl. Acad. Sci. U. S. A. 98:16 (2001), 9116–9121.
124. Noriega, L.G., Feige, J.N., Canto, C. et al., CREB and ChREBP oppositely regulate SIRT1 expression in response to energy availability. EMBO Rep. 12:10 (2011), 1069–1076.
125. Oosterveer, M.H., Schoonjans, K., Hepatic glucose sensing and integrative pathways in the liver. Cell. Mol. Life Sci. 71:8 (2014), 1453–1467.
126. Oosterveer, M.H., Mataki, C., Yamamoto, H. et al., LRH-1-dependent glucose sensing determines intermediary metabolism in liver. J. Clin. Invest. 122:8 (2012), 2817–2826.
127. Cha, J.Y., Repa, J.J., The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J. Biol. Chem. 282:1 (2007), 743–751.
128. Petersen, D.D., Koch, S.R., Granner, D.K., 3′ noncoding region of phosphoenolpyruvate carboxykinase mRNA contains a glucocorticoid-responsive mRNA-stabilizing element. Proc. Natl. Acad. Sci. U. S. A. 86:20 (1989), 7800–7804.
129. Lerin, C., Rodgers, J.T., Kalume, D.E., Kim, S.H., Pandey, A., Puigserver, P., GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1alpha. Cell Metab. 3:6 (2006), 429–438.
130. Fernandez-Marcos, P.J., Auwerx, J., Regulation of PGC-1alpha, a nodal regulator of mitochondrial biogenesis. Am. J. Clin. Nutr. 93:4 (2011), 884S–890.
131. Yoon, J.C., Puigserver, P., Chen, G. et al., Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413:6852 (2001), 131–138.
132. Herzig, S., Long, F., Jhala, U.S. et al., CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 413:6852 (2001), 179–183.
133. Lundasen, T., Hunt, M.C., Nilsson, L.M. et al., PPARalpha is a key regulator of hepatic FGF21. Biochem. Biophys. Res. Commun. 360:2 (2007), 437–440.
134. Potthoff, M.J., Inagaki, T., Satapati, S. et al., FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc. Natl. Acad. Sci. U. S. A. 106:26 (2009), 10853–10858.
135. Kimura, T., Christoffels, V.M., Chowdhury, S. et al., Hypoglycemia-associated hyperammonemia caused by impaired expression of ornithine cycle enzyme genes in C/EBPalpha knockout mice. J. Biol. Chem. 273:42 (1998), 27505–27510.
136. Stayrook, K.R., Bramlett, K.S., Savkur, R.S. et al., Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 146:3 (2005), 984–991.
137. Yamagata, K., Daitoku, H., Shimamoto, Y. et al., Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J. Biol. Chem. 279:22 (2004), 23158–23165.
138. Caron, S., Huaman Samanez, C., Dehondt, H. et al., Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes. Mol. Cell. Biol. 33:11 (2013), 2202–2211.
139. Popescu, I.R., Helleboid-Chapman, A., Lucas, A. et al., The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity. FEBS Lett. 584:13 (2010), 2845–2851.
140. Smushkin, G., Sathananthan, M., Piccinini, F. et al., The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes. Diabetes 62:4 (2013), 1094–1101.
141. Jiang, C., Xie, C., Lv, Y. et al., Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat. Commun., 6, 2015, 10166.
142. Li, F., Jiang, C., Krausz, K.W. et al., Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat. Commun., 4, 2013, 2384.
143. Xie, C., Jiang, C., Shi, J. et al., An intestinal farnesoid X receptor-ceramide signaling axis modulates hepatic gluconeogenesis in mice. Diabetes 66:3 (2017), 613–626.
144. Trabelsi, M.S., Daoudi, M., Prawitt, J. et al., Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat. Commun., 6, 2015, 7629.
145. Fang, S., Suh, J.M., Reilly, S.M. et al., Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat. Med. 21:2 (2015), 159–165.
146. Kir, S., Beddow, S.A., Samuel, V.T. et al., FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331:6024 (2011), 1621–1624.
147. Potthoff, M.J., Boney-Montoya, J., Choi, M. et al., FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab. 13:6 (2011), 729–738.
148. Renga, B., Mencarelli, A., D'Amore, C. et al., Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition. FASEB J. 26:7 (2012), 3021–3031.
149. Lehninger, A.L., Nelson, D.L., Cox, M.M., Lehninger Principles of Biochemistry. 6th ed., 2013, W.H. Freeman, New York.
150. Zoncu, R., Efeyan, A., Sabatini, D.M., mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12:1 (2011), 21–35.
151. Bender, D.A., The metabolism of “surplus” amino acids. Br. J. Nutr. 108:Suppl. 2 (2012), S113–121.
152. Rodés, J., Textbook of Hepatology: From Basic Science to Clinical Practice. 3rd ed., 2007, Blackwell, Malden, Mass.
153. Diez-Fernandez, C., Gallego, J., Haberle, J., Cervera, J., Rubio, V., The study of carbamoyl phosphate synthetase 1 deficiency sheds light on the mechanism for switching on/off the urea cycle. J. Genet. Genomics. 42:5 (2015), 249–260.
154. Lee, B.H., Scaglia, F., Inborn errors of metabolism: from neonatal screening to metabolic pathways. 2015, Oxford University Press, Oxford, New York.
155. Morris, S.M. Jr., Regulation of enzymes of the urea cycle and arginine metabolism. Annu. Rev. Nutr. 22 (2002), 87–105.
156. Ulbright, C., Snodgrass, P.J., Coordinate induction of the urea cycle enzymes by glucagon and dexamethasone is accomplished by three different mechanisms. Arch. Biochem. Biophys. 301:2 (1993), 237–243.
157. Desvergne, B., Michalik, L., Wahli, W., Transcriptional regulation of metabolism. Physiol. Rev. 86:2 (2006), 465–514.
158. Takiguchi, M., Mori, M., Transcriptional regulation of genes for ornithine cycle enzymes. Biochem. J. 312:Pt 3 (1995), 649–659.
159. Okun, J.G., Conway, S., Schmidt, K.V. et al., Molecular regulation of urea cycle function by the liver glucocorticoid receptor. Mol. Metab. 4:10 (2015), 732–740.
160. Kimura, T., Chowdhury, S., Tanaka, T. et al., CCAAT/enhancer-binding protein beta is required for activation of genes for ornithine cycle enzymes by glucocorticoids and glucagon in primary-cultured hepatocytes. FEBS Lett. 494:1–2 (2001), 105–111.
161. Xu, X., Hu, J., McGrath, B.C., Cavener, D.R., GCN2 regulates the CCAAT enhancer binding protein beta and hepatic gluconeogenesis. Am. J. Physiol. Endocrinol. Metab. 305:8 (2013), E1007–1017.
162. Martinez-Jimenez, C.P., Kyrmizi, I., Cardot, P., Gonzalez, F.J., Talianidis, I., Hepatocyte nuclear factor 4alpha coordinates a transcription factor network regulating hepatic fatty acid metabolism. Mol. Cell. Biol. 30:3 (2010), 565–577.
163. Inoue, Y., Hayhurst, G.P., Inoue, J., Mori, M., Gonzalez, F.J., Defective ureagenesis in mice carrying a liver-specific disruption of hepatocyte nuclear factor 4alpha (HNF4alpha). HNF4alpha regulates ornithine transcarbamylase in vivo. J. Biol. Chem. 277:28 (2002), 25257–25265.
164. Li, L., Zhang, P., Bao, Z., Wang, T., Liu, S., Huang, F., PGC-1alpha promotes ureagenesis in mouse periportal hepatocytes through SIRT3 and SIRT5 in response to glucagon. Sci Rep, 6, 2016, 24156.
165. Kitagawa, Y., Hormonal regulation of carbamoyl-phosphate synthetase I synthesis in primary cultured hepatocytes and Reuber hepatoma H-35. Defective regulation in hepatoma cells. Eur. J. Biochem. 167:1 (1987), 19–25.
166. Kitagawa, Y., Ryall, J., Nguyen, M., Shore, G.C., Expression of carbamoyl-phosphate synthetase I mRNA in Reuber hepatoma H-35 cells. Regulation by glucocorticoid and insulin. Biochim. Biophys. Acta 825:2 (1985), 148–153.
167. Nakagawa, T., Lomb, D.J., Haigis, M.C., Guarente, L., SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 137:3 (2009), 560–570.
168. Heibel, S.K., Lopez, G.Y., Panglao, M. et al., Transcriptional regulation of N-acetylglutamate synthase. PLoS One, 7(2), 2012, e29527.
169. Chong, H.K., Infante, A.M., Seo, Y.K. et al., Genome-wide interrogation of hepatic FXR reveals an asymmetric IR-1 motif and synergy with LRH-1. Nucleic Acids Res. 38:18 (2010), 6007–6017.
170. Thomas, A.M., Hart, S.N., Kong, B., Fang, J., Zhong, X.B., Guo, G.L., Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. Hepatology 51:4 (2010), 1410–1419.
171. Gardmo, C., Tamburro, A., Modica, S., Moschetta, A., Proteomics for the discovery of nuclear bile acid receptor FXR targets. Biochim. Biophys. Acta 1812:8 (2011), 836–841.
172. Massafra, V., Milona, A., Vos, H.R. et al., Farnesoid X Receptor Activation Promotes Hepatic Amino Acid Catabolism and Ammonium Clearance. Unpublished, 2016.
173. Lee, J.M., Wagner, M., Xiao, R. et al., Nutrient-sensing nuclear receptors coordinate autophagy. Nature 516:7529 (2014), 112–115.
174. Seok, S., Fu, T., Choi, S.E. et al., Transcriptional regulation of autophagy by an FXR-CREB axis. Nature 516:7529 (2014), 108–111.
175. Vacca, M., Degirolamo, C., Massafra, V. et al., Nuclear receptors in regenerating liver and hepatocellular carcinoma. Mol. Cell. Endocrinol. 368:1–2 (2013), 108–119.
176. Huang, W., Ma, K., Zhang, J. et al., Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 312:5771 (2006), 233–236.
177. Padrissa-Altes, S., Bachofner, M., Bogorad, R.L. et al., Control of hepatocyte proliferation and survival by Fgf receptors is essential for liver regeneration in mice. Gut 64:9 (2015), 1444–1453.
178. Uriarte, I., Fernandez-Barrena, M.G., Monte, M.J. et al., Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut 62:6 (2013), 899–910.
179. Avila, M.A., Moschetta, A., The FXR-FGF19 gut-liver axis as a novel “Hepatostat”. Gastroenterology 149:3 (2015), 537–540.
180. Naugler, W.E., Tarlow, B.D., Fedorov, L.M. et al., Fibroblast growth factor signaling controls liver size in mice with humanized livers. Gastroenterology 149:3 (2015), 728–740 (e715).
181. Fujino, T., Takeuchi, A., Maruko-Ohtake, A. et al., Critical role of farnesoid X receptor for hepatocellular carcinoma cell proliferation. J. Biochem. 152:6 (2012), 577–586.
182. Xie, Y., Wang, H., Cheng, X. et al., Farnesoid X receptor activation promotes cell proliferation via PDK4-controlled metabolic reprogramming. Sci Rep, 6, 2016, 18751.
183. Huang, X., Zeng, Y., Wang, X. et al., FXR blocks the growth of liver cancer cells through inhibiting mTOR-s6K pathway. Biochem. Biophys. Res. Commun. 474:2 (2016), 351–356.
184. Deuschle, U., Schuler, J., Schulz, A. et al., FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model. PLoS One, 7(10), 2012, e43044.
185. Wang, X., Fu, X., Van Ness, C., Meng, Z., Ma, X., Huang, W., Bile acid receptors and liver cancer. Curr. Pathobiol. Rep. 1:1 (2013), 29–35.
186. He, J., Zhao, K., Zheng, L. et al., Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells. Mol. Cancer, 14, 2015, 163.
187. Hsu, P.P., Sabatini, D.M., Cancer cell metabolism: Warburg and beyond. Cell 134:5 (2008), 703–707.
188. Vander Heiden, M.G., Cantley, L.C., Thompson, C.B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:5930 (2009), 1029–1033.
189. Demas, G.E., Chefer, V., Talan, M.I., Nelson, R.J., Metabolic costs of mounting an antigen-stimulated immune response in adult and aged C57BL/6J mice. Am. J. Phys. 273:5 Pt 2 (1997), R1631–1637.
190. Marti, A., Marcos, A., Martinez, J.A., Obesity and immune function relationships. Obes. Rev. 2:2 (2001), 131–140.
191. Hotamisligil, G.S., Erbay, E., Nutrient sensing and inflammation in metabolic diseases. Nat. Rev. Immunol. 8:12 (2008), 923–934.
192. Bensinger, S.J., Tontonoz, P., Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454:7203 (2008), 470–477.
193. Cave, M.C., Clair, H.B., Hardesty, J.E. et al., Nuclear receptors and nonalcoholic fatty liver disease. Biochim. Biophys. Acta, 2016.
194. Venteclef, N., Jakobsson, T., Steffensen, K.R., Treuter, E., Metabolic nuclear receptor signaling and the inflammatory acute phase response. Trends Endocrinol. Metab. 22:8 (2011), 333–343.
195. Kim, I., Morimura, K., Shah, Y., Yang, Q., Ward, J.M., Gonzalez, F.J., Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 28:5 (2007), 940–946.
196. Liu, N., Meng, Z., Lou, G. et al., Hepatocarcinogenesis in FXR −/− mice mimics human HCC progression that operates through HNF1alpha regulation of FXR expression. Mol. Endocrinol. 26:5 (2012), 775–785.
197. Wang, Y.D., Chen, W.D., Wang, M., Yu, D., Forman, B.M., Huang, W., Farnesoid, X., receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 48:5 (2008), 1632–1643.
198. Adorini, L., Pruzanski, M., Shapiro, D., Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov. Today 17:17–18 (2012), 988–997.
199. Gadaleta, R.M., van Erpecum, K.J., Oldenburg, B. et al., Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60:4 (2011), 463–472.
200. Li, Y.T., Swales, K.E., Thomas, G.J., Warner, T.D., Bishop-Bailey, D., Farnesoid X receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler. Thromb. Vasc. Biol. 27:12 (2007), 2606–2611.
201. Massafra, V., Ijssennagger, N., Plantinga, M. et al., Splenic dendritic cell involvement in FXR-mediated amelioration of DSS colitis. Biochim. Biophys. Acta 1862:2 (2016), 166–173.
202. Vavassori, P., Mencarelli, A., Renga, B., Distrutti, E., Fiorucci, S., The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol. 183:10 (2009), 6251–6261.
203. Shaik, F.B., Panati, K., Narasimha, V.R., Narala, V.R., Chenodeoxycholic acid attenuates ovalbumin-induced airway inflammation in murine model of asthma by inhibiting the T(H)2 cytokines. Biochem. Biophys. Res. Commun. 463:4 (2015), 600–605.
204. Hollman, D.A., Milona, A., van Erpecum, K.J., van Mil, S.W., Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. Biochim. Biophys. Acta 1821:11 (2012), 1443–1452.
205. Lyons, C.L., Kennedy, E.B., Roche, H.M., Metabolic inflammation-differential modulation by dietary constituents. Nutrients, 8(5), 2016.
206. Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J. et al., Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385:9972 (2015), 956–965.
207. Mudaliar, S., Henry, R.R., Sanyal, A.J. et al., Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145:3 (2013), 574–582 (e571).
208. Trauner, M., Arrese, M., Wagner, M., Fatty liver and lipotoxicity. Biochim. Biophys. Acta 1801:3 (2010), 299–310.
209. Cai, D., Yuan, M., Frantz, D.F. et al., Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11:2 (2005), 183–190.
210. Bechmann, L.P., Hannivoort, R.A., Gerken, G., Hotamisligil, G.S., Trauner, M., Canbay, A., The interaction of hepatic lipid and glucose metabolism in liver diseases. J. Hepatol. 56:4 (2012), 952–964.
211. Furukawa, S., Fujita, T., Shimabukuro, M. et al., Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114:12 (2004), 1752–1761.
212. Hotamisligil, G.S., Inflammation and metabolic disorders. Nature 444:7121 (2006), 860–867.
213. Shoelson, S.E., Lee, J., Goldfine, A.B., Inflammation and insulin resistance. J. Clin. Invest. 116:7 (2006), 1793–1801.
214. Jena, P.K., Sheng, L., Liu, H.X. et al., Western diet-induced dysbiosis in farnesoid x receptor knockout mice causes persistent hepatic inflammation after antibiotic treatment. Am. J. Pathol. 187:8 (2017), 1800–1813.
215. Schubert, K., Olde Damink, S.W.M., von Bergen, M., Schaap, F.G., Interactions between bile salts, gut microbiota, and hepatic innate immunity. Immunol. Rev. 279:1 (2017), 23–35.